FDA's approval of Merck's Keytruda (pembrolizumab) for use in any patient with a solid tumor with a particular genetic mutation is the first of its kind and could be the herald of a new approach to treating cancer.
The agency announced the accelerated approval of the PD-1 inhibitor May 23, noting "this is the first time the agency...